In particular, Lampalizumab (FCFD4514S) has been shown to reduce the geographic atrophy enlargement in phase II trials of dry AMD in patients who also have a CFI polymorphism, indicating that inhibition of complement is a promising approach. The gene discussed is CFI; the disease is dry age related macular degeneration.